论文部分内容阅读
目的观察乌司他丁辅治缺血性肝炎患者的临床疗效。方法将缺血性肝炎患者120例随机分为研究组与对照组各60例。分析2组患者治疗前与治疗后第1、3天的生化指标:天冬氨酸氨基转移酶(AST)、谷氨酸氨基转移酶(ALT)、血浆中白介素-6(IL-6)、C-反应蛋白(CRP)水平变化。结果与对照组比较,治疗后第1、3天研究组患者AST、ALT、IL-6及CRP水平均低于对照组,差异均有统计学意义(P<0.05)。结论缺血性肝炎患者早期联用乌司他丁可明显降低AST及ALT,减轻肝脏损伤,分析原因可能与乌司他丁拮抗应激,减轻炎性细胞反应有关。
Objective To observe the clinical effect of ulinastatin on patients with ischemic hepatitis. Methods 120 patients with ischemic hepatitis were randomly divided into study group and control group of 60 cases. The biochemical indices of aspartate aminotransferase (AST), glutamate aminotransferase (ALT), interleukin-6 (IL-6) C-reactive protein (CRP) levels change. Results Compared with the control group, the levels of AST, ALT, IL-6 and CRP in the study group were significantly lower than those in the control group on the 1st and 3rd days after treatment (P <0.05). Conclusion Ulinastatin can reduce AST and ALT significantly and reduce liver damage in patients with ischemic hepatitis. The reasons may be related to the antagonism of ulinastatin and the alleviation of inflammatory cell responses.